Skip to main
BEAT
BEAT logo

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam Inc. is poised for substantial growth driven by its proprietary VECG technology and the advancement of AI capabilities, which significantly enhance the detection of cardiac conditions, outperforming traditional ECG methods. The company plans to introduce various new products, including a 12-lead extended wear patch and a smartwatch, broadening its market potential and providing additional revenue streams. With a projected acceleration in sales following the anticipated clearance of its second 510(k) and subscription-based pricing strategies that are expected to escalate alongside AI advancements, the outlook for HeartBeam's revenue growth remains positive.

Bears say

HeartBeam Inc is currently navigating a challenging financial landscape, marked by significant cash burn rates and ongoing losses, which may impede its ability to sustain operations without securing additional funding. The lengthy FDA clearance process for its VECG technology and initial telehealth products introduces uncertainty regarding market entry and revenue generation timelines. Furthermore, potential competition in the medical technology sector could pressure HeartBeam's market share and profitability prospects, raising concerns about its long-term financial viability.

HeartBeam (BEAT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Buy based on their latest research and market trends.

According to 9 analysts, HeartBeam (BEAT) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.